Plus Therapeutics announced on July 23, 2025, that it received notice of an advance payment of $1.6 million from the Cancer Prevention and Research Institute of Texas (CPRIT). This payment is part of the company’s previously awarded $17.6 million grant.
This latest CPRIT disbursement, along with an additional $6 million in funding expected over the next 12 months, provides significant non-dilutive financing. This support strengthens the company's capital position for long-term growth.
The funding specifically supports and accelerates the company’s clinical development of REYOBIQ™ for the ReSPECT-LM dose optimization trial. It also further develops the company’s CNSide LM diagnostic test as a key pivotal trial endpoint.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.